Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 485: (TSXV: $DB.V) (OTCQB: $DBCCF), (CSE: $XCX.C) (TSXV: $NUMI.V)
Today's podcast sponsored by Cannabis Suisse Corp.
(OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in
Switzerland
Delta, Kelowna, BC, October 22, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/102220-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/10221DB-DBCCF-XCX-NUMI.asp
Hear the investor ideas potcast on
Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s podcast is
sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis
cultivation and distribution company in Switzerland, for recreational tobacco
products and medical CBD oils. The Company's facilities for producing cannabis
are based in Dietikon, Switzerland, and contain the art surveillance equipment
to enable an around the clock webcast. Cannabis Suisse grows high quality,
organic cannabis with sustainable, all-natural principles. The Company's
products are laboratory tested to ensure the end users have access to a
standardized, safe and consistent product. Cannabis Suisse proprietary
trademarked MoldStandard is a quantitative microbiology method for analyzing
yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary
trademarked CannaMec is a method for quantifying and removing residual solvents
during packaging and storage of CBD products. Cannabis Suisse Corp. currently
sells via a distribution network of Swiss retailers and online shops, under the
retail brand Alpine Cannabis.
In
today’s podcast we look at a few public and private company announcements.
Decibel
Cannabis Company Inc. (TSX-V:DB) (OTCQB:DBCCF), a premium cannabis producer and
retailer, announced the launch of cannabis derivative
products produced at its extraction facility, The Plant.
"Our product strategy is driven
by our intimate knowledge of the end consumer through our Prairie Records
retail stores," said Adam Coates, Chief Growth Officer of Decibel.
"This position allows for insights such as identifying whitespace
opportunities the current market is not fulfilling, and understanding key
product attributes consumers are looking for in established formats. With these
insights, we are launching black market quality concentrates, high potency,
strain specific vapes and the CÜE line of fast acting 10mg THC shot style
beverages."
Product
Launch Highlights
● 10 Product Skus Launched: Achieved
its first 57 product sku registrations in Western Canada and a supply agreement
with the Ontario Cannabis Retail Corporation, with 10 skus currently available
in cannabis retail stores across British Columbia, Alberta and Saskatchewan.
The first shipments of products were delivered in late Q3.
● Blendcraft by Qwest Concentrates: Decibel's
first derivative product launches under the Blendcraft by Qwest banner with 4
skus of Wax (crumble) and 4 skus of Shatter. These high potency, in demand
concentrates compliment the rare cultivar, craft dried flower products the
Company produces under the Qwest Family of Brands.
● General Admission Vapes: Decibel
has launched its new brand, General Admission, with four strain specific vapes
(Berry G 33, Tropic GSC, Lemon Ice and Tropic Thunder) in 0.45g and 0.95g
cartridges, and 0.3g disposable formats. With high potency THC dominant and
THC/CBD balanced formulations and a strong value-for-price ratio, first
shipments of these products have been successful with re-orders from initial
product shipments achieved within the first week of launch.
● CÜE Fast Acting Cannabis Shots: The
Company has entered into a definitive agreement with Origin Scientific Inc., a
private Canadian company, to manufacture and distribute CÜE fast acting
cannabis shots. CÜE has developed an industry leading, clinically proven and
patented nano encapsulation technology that has been formulated into a
fast-acting cannabis infused shot style beverage. "CÜE Lemon Tea", a
59ml cannabis shot with 10mg of THC and 30mg of naturally occurring caffeine is
expected to be the initial product offering, which the Company anticipates to
be available for sale in November.
AMP
German Cannabis Group Inc. (CSE: XCX) providing German patients with a
wide range of pharmaceutical grade medical cannabis products, announced it will be adding Little Green Pharma Ltd. (ASX: LGP) cannabis oil medicines to its
catalogue for sale in Germany beginning in November 2020 subject to obtaining a
BtM-registration (narcotic drug licence) of these products on behalf of AMP.
AMP is looking forward to offering
premium EU-GMP full plant extract cannabis oil medicines branded under the LGP
Classic brand, produced by the same consistent strains. AMP wants to introduce the LGP brand to the
German market by selling "LGP Classic 20:5 Oils" (THC dominant) and
additional products in the near term once AMP has established the brand in the
German market. Whereas LGP`s full plant extracts originate from the same
cannabis plants, many other cannabis extracts are sourced from varying cannabis
plants.
Little Green Pharma is licenced to
cultivate and produce medical cannabis in Australia and has obtained the
required licences and permits to export to Germany. Little Green Pharma has its
own Therapeutic Goods Administration ("TGA") GMP licensed
manufacturing facility in addition to a six-year, exclusive manufacturing
agreement with a third-party TGA-GMP licensed contract manufacturer based in Western
Australia. The TGA-GMP certification, granted by Australia's Department of
Health, is recognized by EU regulatory authorities as meeting EU-GMP standards
enabling LGP products to be sold in Germany.
Dr. Stefan Feuerstein, Director and
President of AMP, said: "We had a lot of requests for medical cannabis
oils during our recent sales trip through Germany, where we met with
medium-sized distributors and large pharmacists that are specializing in
medical cannabis. To meet this demand,
we are introducing the premium LGP Classic brand as our first extract brand for
the German market. We wanted our first extract in our product line to be a
premium, full plant extract that our sales team can introduce along with our
other medical cannabis flower products. We will be adding additional cannabis
oils in the coming months to satisfy our customers' strong demand for this
product line."
Ms. Fleta Solomon, Managing Director
of Little Green Pharma, commented,
"Our focus is on producing the highest quality cannabis medicines for
Australia and other countries where medicinal cannabis has been legalized. We
are proud to be the first Australian company to supply Germany, the leading
medicinal cannabis market in Europe, and that AMP will be introducing the LGP
Classic brand. We expect strong sales
from AMP as they immediately launch and invest in introducing our LGP Classic
20:5 oil to the German market and additional LGP Classic products in the near
term."
Numinus Wellness
Inc. (TSXV: NUMI), a company creating an ecosystem
of health solutions centred on developing and supporting the safe,
evidence-based, accessible use of psychedelic-assisted psychotherapies, announced that they have harvested the first
legal flush of Psilocybe mushrooms in
Canada by a public company under its Health Canada-issued Controlled Drugs and
Substances Dealer's Licence. This news coincides with other recent developments
by Numinus Bioscience, the Company's 7,000 square foot analytics and research
laboratory, which is focused on handling various psychedelic substances and
developing analytical methods and formulations for the evolving psychedelics
space.
"The
first harvest of legally grown Psilocybe
mushrooms is a significant milestone for the whole industry" said Michael
Tan, Chief Operating Officer. "Now, we can progress with research and
development of standardized cultivation, extraction, and testing methods and
exploring product formulations to support safe, evidence-based, accessible
psychedelic-assisted psychotherapy, as well as build a sequenced spore library."
Dennis
McKenna, renowned ethnopharmacologist, Co-founder of the Heffter Research
Institute, Founder of the McKenna Academy of Natural Philosophy, and member of
Numinus' General Advisory Council, adds, "While there is a place for
synthetic psilocybin in clinical practice, well-characterized and standardized
extracts of natural forms of psilocybin i.e., mushrooms, cultivated and
processed under stringent quality control protocols, are the wave of the future
as therapeutic psilocybin gains acceptance. Given a choice, many people would
prefer the option to use natural psilocybin. Mushrooms have been used in
traditional medicine for literally thousands of years, and hence, they are just
that much closer to these ancient traditions. Natural mushroom extracts are also
likely to be far more affordable compared to synthetic psilocybin, and that is
an important consideration when it comes to ensuring accessibility to this
medicine which can be so beneficial to many people. Cost should not be a
barrier to access these medicines, and the use of mushroom extracts will help
ensure those who need them most can benefit from psilocybin therapies."
Numinus
Bioscience is establishing itself at the forefront of analytical testing for
psychedelic substances, as a centre of excellence for psychedelic product
research and development, and as an ancillary for psychedelic therapy clinical
trials. Health Canada licences, scientific expertise, and state-of-the-art
technologies facilitate ongoing innovation, while revenue from high-throughput
contract cannabis testing is reinvested to further its psychedelic initiatives.
In
addition to today's announcement, Numinus includes in its recent developments
an amendment application to its Health Canada-issued Controlled Drugs and
Substances Licence. The current licence permits testing, import and export,
storage and distribution of MDMA, Psilocybin, Psilocin, DMT, and Mescaline as
well as the undertaking of novel mycological research initiatives. The
amendment will additionally permit the sale of Psilocybe mushroom fruiting bodies and extract for clinical
research protocols and the development of standardized testing for additional
psychedelic substances.
Numinus
is also proud to announce the recent appointment of Sharan Sidhu, regulatory expert
and policy advisor for restrictive high growth industries, as Science Officer
and General Manager. Sidhu brings extensive experience as a hub between
academia, industry, and governing directorates to align research objectives
with regulatory compliance. She has been a key strategist for research
roadmaps, core initiatives, the development of IP, and the development of
compliance requirements including LIMS, GLP/GMP, GACP, and ISO Standards.
"Sharan's
experience and leadership are already proving instrumental in establishing
Numinus Bioscience as a centre of excellence and major industry player in the
delivery of safe, evidence-based, accessible psychedelic-psychotherapy,"
said Payton Nyquvest, CEO, Founder, and Chairman. "We are honoured to have
her join us on our mission."
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks
and other ideas on our site using our list of
top stock trading apps including
Robinhood, Acorn, Stash and others.
To hear more
Investorideas.com podcasts visit:
https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on
Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
No comments:
Post a Comment